Assessment of Fitness After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients

Sponsor
Michelle Mossa (Other)
Overall Status
Completed
CT.gov ID
NCT01334593
Collaborator
(none)
25
1
11
2.3

Study Details

Study Description

Brief Summary

Neoadjuvant chemoradiotherapy (NACRT) prior to surgery for lower gastrointestinal (colon and rectal) cancer is associated with improved survival, but also adversely affects physical fitness, potentially rendering patients unfit for major surgery or increasing the risk of adverse outcome (death and serious complications) after major surgery. The investigators aim to obtain pilot data showing that neoadjuvant chemoradiotherapy (NACRT)reduces objectively measured exercise capacity (fitness).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Purpose: To evaluate the effects of chemoradiotherapy on pre-operative fitness of patients prior to major colorectal cancer surgery.

    Design: Patients will act as their own case-control.

    Patients will be consented at the earliest available opportunity following the decision that they have surgically treatable disease and they consent to pre-operative NACRT. Consent for the study will be gained as an outpatient. At "visit 1" patients will undergo CPET, as is our current standard practice, prior to commencing neoadjuvant chemoradiotherapy. As part of the assessment, they will have pulmonary function testing (static lung volumes, lung diffusing capacity). They will then undergo 6 weeks of long course NACRT, as is standard current practice at our institution. At "visit 2", approximately four to six weeks following chemoradiotherapy another CPET test will be repeated. This is also current standard practice at our institution. Data from visit 1 and visit 2 will be compared in a paired manner. A statistician will be consulted to assess the degree of normality of the data, the statistical tests to use, and for power calculations. At no point will any treatments be postponed or changed solely for the purposes of collecting data for the research.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    25 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Effect of Neoadjuvant Chemoradiotherapy on Exercise Capacity in Colrectal Cancer Patients
    Study Start Date :
    Aug 1, 2011
    Actual Primary Completion Date :
    Jul 1, 2012
    Actual Study Completion Date :
    Jul 1, 2012

    Arms and Interventions

    Arm Intervention/Treatment
    Rectal Cancer

    Outcome Measures

    Primary Outcome Measures

    1. Measurement of Cardio Pulmonary exercise test related parameters (VO2 at AT) pre and post neoadjuvant chemoradiotherapy in rectal cancer patients. [2 years]

      Exercise capacity (fitness) before and after NACRT will be assessed using CPET.We have pilot data on an upper gastrointestinal cancer cohort that shows that neoadjuvant chemotherapy alone results in lower levels of fitness (mean fall VO2@LT of 2.19ml/kg/min), which relates to survival before stomach and oesophageal surgery in a group of patients in Liverpool. These data also suggest that the insult of chemotherapy and surgery increases mortality

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients listed to undergo neoadjuvant chemoradiotherapy for downstaging of colorectal cancer, with a view to undergo elective colorectal surgery at Aintree University Hospitals.
    Exclusion Criteria:
    • Unable to consent.

    • Under 18 years of age.

    • Significant ischaemic changes of >1.5mm symptomatic and > 2mm asymptomatic observed on routine cardiopulmonary exercise test.

    • Any other absolute contraindications to CPET based on the ATS guidelines.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Aintree University Hospitals Liverpool Merseyside United Kingdom L7 8XP

    Sponsors and Collaborators

    • Michelle Mossa

    Investigators

    • Principal Investigator: Malcolm A West, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michelle Mossa, Deputy Research and Development Director, Liverpool University Hospitals NHS Foundation Trust
    ClinicalTrials.gov Identifier:
    NCT01334593
    Other Study ID Numbers:
    • 11/H1002/12b
    First Posted:
    Apr 13, 2011
    Last Update Posted:
    Jan 3, 2013
    Last Verified:
    Dec 1, 2012

    Study Results

    No Results Posted as of Jan 3, 2013